BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33741738)

  • 1. Paradoxical androgen receptor regulation by small molecule enantiomers.
    Patsch K; Liu C; Zapotoczny G; Sun Y; Sura H; Ung N; Sun RX; Haliday B; Yu C; Aljehani M; Lee JSH; Kashemirov BA; Agus DB; McKenna CE; Ruderman D
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33741738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
    Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
    Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
    Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
    Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
    Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
    Fancher AT; Hua Y; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2019; 17(8):364-386. PubMed ID: 31502857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hits Discovery on the Androgen Receptor: In Silico Approaches to Identify Agonist Compounds.
    Réau M; Lagarde N; Zagury JF; Montes M
    Cells; 2019 Nov; 8(11):. PubMed ID: 31766271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
    Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
    Siddique HR; Mishra SK; Karnes RJ; Saleem M
    Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction.
    Wahl J; Smieško M
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor.
    Paul N; Carabet LA; Lallous N; Yamazaki T; Gleave ME; Rennie PS; Cherkasov A
    J Chem Inf Model; 2016 Dec; 56(12):2507-2516. PubMed ID: 28024400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
    Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
    Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.
    Dalal K; Munuganti R; Morin H; Lallous N; Rennie PS; Cherkasov A
    Methods Mol Biol; 2016; 1443():31-54. PubMed ID: 27246333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
    Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of a Computational Model for Androgen Receptor Activity.
    Kleinstreuer NC; Ceger P; Watt ED; Martin M; Houck K; Browne P; Thomas RS; Casey WM; Dix DJ; Allen D; Sakamuru S; Xia M; Huang R; Judson R
    Chem Res Toxicol; 2017 Apr; 30(4):946-964. PubMed ID: 27933809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.